DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.

[1]  C. Jacobs,et al.  Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling. , 2006, Bone.

[2]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[3]  E. Schwarz,et al.  The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone , 2005, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[4]  M. Malaise,et al.  Interleukin-6: An osteotropic factor influencing bone formation? , 2005, Bone.

[5]  N. Nonomura,et al.  Prostate cancer mediates osteoclastogenesis through two different pathways. , 2005, Cancer letters.

[6]  井上 均.  Prostate cancer mediates osteoclastogenesis through two different pathways , 2005 .

[7]  R. Vessella,et al.  Osteoprotegerin in prostate cancer bone metastasis. , 2005, Cancer research.

[8]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[9]  C. Colombeix,et al.  Downregulation of Osteoblast Markers and Induction of the Glial Fibrillary Acidic Protein by Oncostatin M in Osteosarcoma Cells Require PKCδ and STAT3 , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  M. Padrines,et al.  RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.

[11]  J. Chirgwin,et al.  Tumor-bone cellular interactions in skeletal metastases. , 2004, Journal of musculoskeletal & neuronal interactions.

[12]  Kwan Tat Steeve,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004 .

[13]  W. Dougall,et al.  Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. , 2003, Cancer research.

[14]  J. Chirgwin,et al.  Transforming growth factor-beta in osteolytic breast cancer bone metastases. , 2003, Clinical orthopaedics and related research.

[15]  Hong-Hee Kim,et al.  Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. , 2003, Biochemical and biophysical research communications.

[16]  T. Guise.  The vicious cycle of bone metastases. , 2002, Journal of musculoskeletal & neuronal interactions.

[17]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[18]  F. Hamdy,et al.  Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. , 2002, Cancer research.

[19]  G. Risbridger,et al.  An in vivo model of prostate carcinoma growth and invasion in bone , 2002, Cell and Tissue Research.

[20]  P. Kostenuik,et al.  Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  L. Hofbauer,et al.  Receptor activator of nuclear factor‐κB ligand and osteoprotegerin , 2001 .

[22]  A. Mizokami,et al.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.

[23]  R. Vessella,et al.  Osteoprotegerin and rank ligand expression in prostate cancer. , 2001, Urology.

[24]  E. Keller,et al.  Interleukin-6 and prostate cancer progression. , 2001, Cytokine & growth factor reviews.

[25]  R. Rizzoli,et al.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer , 2000, British Journal of Cancer.

[26]  D. Lacey,et al.  The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.

[27]  S. Morony,et al.  Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Simons,et al.  Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.

[29]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[30]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.

[31]  B. Bonavida,et al.  Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines. , 1998, Anticancer Research.

[32]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[33]  N. Clarke,et al.  Morphometric evidence for bone resorption and replacement in prostate cancer. , 1991, British journal of urology.

[34]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[35]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[36]  D. Heymann,et al.  RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. , 2006, International journal of oncology.

[37]  M. Hansen,et al.  Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  S. Kwan Tat,et al.  IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004, Cytokine & growth factor reviews.

[39]  R. Kitazawa,et al.  Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. , 2003, The Journal of biological chemistry.

[40]  J. Chirgwin,et al.  Molecular mechanisms of tumor-bone interactions in osteolytic metastases. , 2000, Critical reviews in eukaryotic gene expression.

[41]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[42]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[43]  J. Bingham.  Letter: Lower oesophageal sphincter. , 1974, Lancet.